查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837137

按给药途径、治疗方法、结核病类型和分销管道分類的结核病药物市场 - 全球预测 2025-2032

Tuberculosis Drugs Market by Route Of Administration, Treatment Regimen, Tuberculosis Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年结核病药物市场规模将成长至 33.8 亿美元，复合年增长率为 6.46%。

主要市场统计数据
基准年2024年 20.4亿美元
预计2025年 21.8亿美元
预测年份：2032年 33.8亿美元
复合年增长率（%） 6.46%

简洁、策略性地介绍了影响结核病药物的临床、监管和商业性背景以及製定领导者所需做出的决策。

本执行摘要总结了当代影响结核病药物因应的动态，并组装了高阶领导者必须回答的策略问题。它汇集了临床进展、监管变革、供应链现状、付款方和提供者的行为以及竞争定位，为董事会层面的讨论和商业规划提供了简洁的参考。本书面向相关人员明确发展动能、风险集中点以及临床实务中治疗模式的演变。

本书首先强调了结核病对全球公共卫生的持续重要性，以及重要的治疗方法创新。近年来，临床医生和国家计画越来越重视针对多种抗药性疾病的短期全口服治疗方案，而诊断技术的改进也使得早期发现和更精准的治疗选择成为可能。这些临床变革，加上供应链依赖性、价格压力和监管调整，为製造商、经销商和临床网络带来了机会和必要性。

本介绍涵盖了转型转变、关税相关影响、细分和区域影响、竞争情报、可操作的建议和调查方法，目的是为决策者提供平衡临床现实与商业性执行的综合观点。

最近的临床突破、诊断整合和采购现代化如何从根本上重塑结核病药物治疗途径和商业策略

由于临床创新、治疗指南修订以及技术驱动的诊断技术，结核病药物治疗格局正在发生重大变化。全口服方案的采用和短期疗程方案的整合正开始改变许多高负担地区的处方习惯，新型药物的出现也正在改变多重抗药性结核病的临床治疗路径。同时，对以病人为中心的医疗服务和分散式治疗的日益重视，促使支付方和卫生系统优先考虑能够减少住院率和提高依从性的方案。

这些治疗方法进展伴随着法律规范和采购惯例的变化，从而促进了针对未满足需求的药物的更快核准。治疗产品製造商和临床专案经理必须应对这样一个环境：真实世界证据和专案数据在报销讨论和国家治疗政策更新中的重要性日益凸显。此外，对照护现场和分子诊断的投资正在改善病例检测，并带来更具针对性的治疗方法方案，从而在诊断能力与特定药物方案需求之间建立紧密的联繫。

总体而言，这些竞争变化正在重塑竞争动态，迫使供应商透过处方集获取、低温运输和配送支援等服务，以及将临床试验结果转化为规模化应用的伙伴关係关係来差异化竞争。最终将形成一个更整合的生态系统，其中治疗价值不仅取决于疗效，还取决于交付模式、依从性支持以及与国家结核病控制重点的一致性。

评估 2025 年美国关税如何重塑整个结核病药物供应网络的供应链弹性、筹资策略和购买行为

2025年美国实施的关税和贸易措施，正在对支持结核病治疗供应的全球医药供应链和采购管道造成显着的摩擦。许多成品药和原料药是透过复杂的国际网络购买的。征收关税和相关管控要求将增加到岸成本，改变供应商的选择标准，并延长关键投入的前置作业时间。这些影响将波及采购週期、库存政策以及製造商、经销商和公共卫生采购商之间的合约谈判。

为此，製造商和国家专案正在审查筹资策略，透过近岸外包和替代原料药供应商的资格认证来加速供应商多元化，以降低单一来源风险。付款人和大型机构采购商正在审查合约条款和库存缓衝，以在应对价格压力的同时保持供应的连续性。监管机构和海关部门也在製定程序指南，以加快基本药物的供应，但关税政策的不确定性仍可能鼓励囤积和保守采购，从而扭曲正常的采购模式。

对商业相关人员，关税环境凸显了营运敏捷性和服务成本优化的策略重要性。能够重组供应链、在地化关键製造流程并展示弹性通路的公司将减少贸易政策波动的影响。同时，公共卫生计画必须在财务管理和以病人为中心的服务交付之间取得平衡，权衡短期成本与长期需求（例如持续照护和计画成果）。

详细的細項分析揭示了给药途径、治疗方案的复杂性、疾病概况和分销管道如何相互作用，从而塑造您的产品和服务策略

细分洞察揭示了临床用例和通路之间的差异化动态，为产品定位、服​​务模式和商业化计划提供了启示。根据给药途径，此领域分为注射疗法和口服疗法。随着临床医生倾向于缩短住院时间和提高患者依从性，口服疗法将继续扩展，而注射疗法将在特定临床情况和同情用药场景中保持一席之地。根据治疗方法，相关人员必须处理个人化治疗方案与标准化长期和短期治疗方案的共存。虽然个人化治疗方案需要灵活的供应和诊断联繫，但标准化的长期和短期方案可受益于简化的采购和专案部署。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 贝达喹啉和德拉马尼的扩大获取计画加速了耐多药结核病高负担国家的治疗选择
  • 提高抗药性和药物敏感结核病患者对基于 pretomanid 的较短疗程治疗方案的依从性
  • 开发针对持续性结核分枝桿菌的新型Oxazolidinone衍生物以缩短治疗週期
  • 整合全基因组定序和药物敏感性测试实现个人化多模态结核病治疗
  • 客製化固定剂量组合产品的普及，以提高儿童结核病治疗的剂量准确性和依从性
  • 监管机构核准第二代硝基咪唑化合物，旨在克服结核分枝桿菌菌株的抗药性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 依给药途径分類的结核病药物市场

  • 注射
  • 口服

9. 结核病药物市场（治疗方法）

  • 个人化治疗方案
  • 长距离路线
  • 短期课程

第 10 章：结核病药物市场（依结核病类型划分）

  • 肺外
  • 肺

第 11 章结核病药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十二章结核病药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章结核病药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章各国结核病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Johnson & Johnson
    • Lupin Limited
    • Cipla Limited
    • Viatris Inc
    • Sun Pharmaceutical Industries Limited
    • Otsuka Pharmaceutical Co., Ltd.
    • Dr. Reddy's Laboratories Limited
    • Teva Pharmaceutical Industries Limited
    • Glenmark Pharmaceuticals Limited
    • F. Hoffmann-La Roche Ltd
Product Code: MRR-03252A5F9277

The Tuberculosis Drugs Market is projected to grow by USD 3.38 billion at a CAGR of 6.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.04 billion
Estimated Year [2025] USD 2.18 billion
Forecast Year [2032] USD 3.38 billion
CAGR (%) 6.46%

A concise and strategic introduction framing the clinical, regulatory, and commercial contexts shaping tuberculosis drugs and the decisions leaders must make

This executive summary synthesizes contemporary dynamics shaping pharmaceutical responses to tuberculosis and frames the strategic questions that senior leaders must answer. The content aggregates clinical advances, regulatory shifts, supply chain realities, payer and provider behaviors, and competitive positioning to create a concise reference that supports board-level discussions and commercial planning. It is written for stakeholders who require clarity on where momentum exists, where risk concentrations lie, and how treatment paradigms are evolving in clinical practice.

The opening context highlights the sustained global public health imperative posed by tuberculosis alongside significant therapeutic innovation. Over recent years, clinicians and national programs have increasingly emphasized shorter, all-oral regimens for many forms of drug-resistant disease, while diagnostics improvements are enabling earlier detection and more precise treatment selection. These clinical shifts intersect with supply chain dependencies, pricing pressures, and regulatory adaptations, creating both opportunities and imperatives for manufacturers, distributors, and clinical networks.

This introduction positions the subsequent sections to examine transformative shifts, tariff-related impacts, segmentation- and region-specific implications, competitor intelligence, actionable recommendations, and the methodology underpinning the research. The aim is to equip decision-makers with an integrated perspective that balances clinical realities with commercial execution.

How recent clinical breakthroughs, diagnostic integration, and procurement modernization are fundamentally reshaping treatment pathways and commercial strategies for tuberculosis therapeutics

The landscape for tuberculosis therapeutics is undergoing transformative shifts driven by clinical innovation, revised treatment guidelines, and technology-enabled diagnostics. Adoption of all-oral regimens and the consolidation of shorter-course options have begun to change prescribing habits in many high-burden settings, while the emergence of novel agents has altered clinical pathways for multidrug-resistant disease. At the same time, increased emphasis on patient-centered care and decentralization of treatment delivery is prompting payers and health systems to prioritize regimens that reduce hospitalization and improve adherence.

These therapeutic advances are accompanied by changes in regulatory frameworks and procurement practices that favor accelerated pathways for drugs addressing unmet needs. Manufacturers and clinical program managers must navigate an environment where real-world evidence and programmatic data carry rising weight in reimbursement discussions and national treatment policy updates. Additionally, investment in point-of-care and molecular diagnostics is improving case detection and enabling more targeted therapy selection, creating stronger linkages between diagnostic capacity and demand for specific drug regimens.

Collectively, these shifts are reshaping competitive dynamics, forcing suppliers to differentiate through formulary access, service offerings such as cold chain and distribution support, and partnerships that connect clinical trial outcomes to implementation at scale. The result is a more integrated ecosystem in which therapeutic value is determined not only by efficacy but also by delivery model, adherence support, and alignment with national TB control priorities.

Assessment of how 2025 tariff measures in the United States are reshaping supply chain resilience, sourcing strategies, and procurement behavior across tuberculosis drug supply networks

The introduction of tariffs and trade measures in the United States during 2025 is creating measurable friction across global pharmaceutical supply chains and procurement channels that support tuberculosis drug availability. Many finished pharmaceuticals and active pharmaceutical ingredients are sourced through complex international networks; the imposition of duties and related administrative requirements increases landed costs, alters supplier selection calculus, and extends lead times for critical inputs. These effects ripple through procurement cycles, inventory policies, and contractual negotiations between manufacturers, distributors, and public health purchasers.

In response, manufacturers and national programs are reassessing sourcing strategies and accelerating supplier diversification, including nearshoring and qualifying alternative API suppliers to mitigate single-source exposure. Payers and large institutional purchasers are revisiting contractual terms and inventory buffers to preserve continuity of supply while managing price pressures. Regulatory agencies and customs authorities are also evolving procedural guidance to expedite essential medicines, but uncertainty in tariff policy can still incentivize stockpiling or conservative procurement that distorts normal purchasing patterns.

For commercial stakeholders, the tariff environment increases the strategic importance of operational agility and cost-to-serve optimization. Firms that can reconfigure supply chains, localize critical manufacturing steps, and demonstrate resilient distribution channels will reduce exposure to trade-policy volatility. Meanwhile, public health programs will need to weigh short-term cost implications against the longer-term imperatives of treatment continuity and programmatic outcomes, balancing fiscal stewardship with patient-centered service delivery.

Deep segmentation analysis revealing how route of administration, regimen complexity, disease presentation, and distribution channels interact to shape product and service strategies

Segmentation insight reveals differentiated dynamics across clinical use cases and distribution pathways, with implication for product positioning, service models, and commercialization plans. Based on route of administration, the landscape is divided between injectable and oral therapies, where oral regimens continue to expand as clinicians favor reduced hospitalization and improved patient adherence, while injectable options retain niche roles for specific clinical circumstances and compassionate-use scenarios. Based on treatment regimen, stakeholders must navigate the coexistence of individualized regimen approaches alongside long-course and short-course standardized regimens; individualized regimens require flexible supply and diagnostic linkage, whereas standardized long-course and short-course options benefit from streamlined procurement and programmatic rollout.

Based on tuberculosis type, the clinical and logistical requirements differ substantially between extrapulmonary and pulmonary presentations, with extrapulmonary disease often necessitating longer diagnostic workups and multidisciplinary care, and pulmonary disease remaining the major driver of transmission-control strategies. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each present distinct commercialization considerations: hospital pharmacy channels demand integration with inpatient formularies and clinical stewardship programs, online pharmacy channels require robust cold chain and regulatory compliance for cross-border delivery, and retail pharmacy channels depend on community-level prescribing patterns and patient access programs.

These segmentation axes interact: for example, the adoption of short-course oral regimens for pulmonary TB may shift demand toward retail and online distribution for outpatient management, while individualized regimens for extrapulmonary or drug-resistant cases will concentrate demand in hospital pharmacy and specialty distribution channels. Effective commercial strategies will therefore align product portfolios and service propositions with route-of-administration preferences, regimen complexity, disease presentation, and channel-specific operational requirements.

Regional intelligence describing how epidemiology, health system capacity, procurement modalities, and manufacturing footprints uniquely shape tuberculosis drug access and implementation

Regional dynamics underscore how epidemiology, health system capacity, and procurement practices create distinct contexts for deployment and commercialization of tuberculosis therapeutics. In the Americas, national programs and private-sector providers coexist with diversified manufacturing footprints, and payer engagement focuses on balancing public health imperatives with budgetary constraints; partnerships between public procurement agencies and regional manufacturers influence access strategies. In Europe, Middle East & Africa, heterogeneity is significant: high-income European systems concentrate on novel treatment adoption and integration with diagnostics, while many countries within the Middle East & Africa region face infrastructural constraints that prioritize simple, resilient regimens and supply chains able to operate under logistical stress.

In the Asia-Pacific region, where a substantial burden of tuberculosis persists in several countries, the interplay of local manufacturing capabilities, large-scale public procurement programs, and evolving treatment guidelines drives rapid implementation of newer regimens in some settings while others continue incremental transitions. Regional procurement mechanisms, donor-funded programs, and public-private partnerships remain important levers to accelerate access, but local regulatory harmonization and capacity building for diagnostics are often prerequisites for widescale adoption.

Across all regions, tailored strategies that account for national policy environments, distribution network maturity, and clinician practice patterns will be essential. Commercial and public health actors should calibrate engagement models to regional priorities, investing in diagnostic linkage, training, and supply-chain strengthening where needed to translate therapeutic potential into measurable patient benefit.

Analysis of competitive positioning and partnership models among manufacturers, generic producers, and service-oriented entrants that determine access pathways and commercialization success

Competitive and partnership dynamics among pharmaceutical firms, generic manufacturers, and specialty suppliers continue to shape access pathways and therapeutic mix. Established producers of foundational anti-tuberculosis agents maintain critical relationships with national procurement agencies and hospital formularies, which creates barriers to rapid displacement but also opportunities for differentiated offerings that reduce total cost of care or simplify logistics. At the same time, innovators bringing newer oral regimens and novel agents are pursuing strategic alliances with diagnostic companies, non-governmental implementers, and contract manufacturers to accelerate inclusion in national treatment guidelines and secure supply commitments.

Generic manufacturers play a central role in expanding geographic access, particularly through licensed production and voluntary licensing frameworks that enable broader distribution in low- and middle-income countries. Specialty suppliers and contract manufacturing organizations are increasingly important partners for scaling production of newer compounds and ensuring compliance with international quality standards. Meanwhile, service-oriented entrants that package therapeutics with adherence support tools, digital monitoring platforms, and supply-chain visibility solutions are creating competitive differentiation beyond the core molecule.

For incumbent and new entrants alike, winning in this environment requires a dual focus on clinical evidence generation and implementation science. Firms that can demonstrate real-world effectiveness, safety across diverse populations, and cost-and-care pathway advantages will gain traction with payers and national programs. Strategic licensing, targeted R&D investments, and flexible commercial models that accommodate both programmatic procurement and private-sector channels will be decisive features of successful company strategies.

Actionable recommendations for industry leaders to align diagnostics, diversify supply chains, and deploy integrated service models that secure continuity and accelerate appropriate regimen adoption

Leaders across industry, public health programs, and procurement agencies should adopt a set of practical actions to navigate clinical evolution, supply chain turbulence, and policy uncertainty. First, prioritize integration between diagnostics and therapeutics to ensure regimen selection aligns with rapid and accurate case detection; investments in molecular diagnostics and training will improve regimen appropriateness and reduce downstream costs associated with treatment failure. Second, diversify supplier networks for critical APIs and finished dosage forms while building conditional local manufacturing options where feasible to reduce exposure to trade-policy disruptions and single-source dependencies.

Third, design commercial offerings that combine product access with implementation support, leveraging digital adherence tools, patient education, and tailored service bundles to enhance uptake and real-world outcomes. Fourth, engage proactively with regulatory authorities and national programs to provide robust real-world evidence and post-marketing safety data that can accelerate guideline inclusion. Finally, adapt contracting and pricing approaches to accommodate public-sector procurement cycles and donor-funded programs, while preserving commercial viability through tiered access models and outcome-linked agreements.

Taken together, these steps constitute a pragmatic roadmap to sustain supply continuity, accelerate appropriate regimen adoption, and align commercial execution with public health objectives. Organizations that operationalize these recommendations will be better positioned to deliver clinical value and maintain resilient operations amid evolving policy and clinical landscapes.

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, supply-chain mapping, and scenario analysis to generate actionable intelligence

This research synthesizes primary and secondary intelligence through a structured methodology designed to produce actionable insights while preserving analytical rigor. The approach combined targeted stakeholder interviews with clinicians, procurement officials, and senior executives across manufacturers and distribution channels, supplemented by a systematic review of peer-reviewed clinical literature, regulatory guidance, and programmatic reports up to mid-2024. Data triangulation was applied to reconcile differing perspectives and identify persistent themes across geographies and stakeholder types.

Qualitative findings were contextualized by supply-chain mapping exercises and scenario analysis to assess operational sensitivities to trade-policy changes and sourcing disruptions. Case studies illustrating successful regimen adoption and implementation were selected to highlight transferable lessons and operational enablers. The research also incorporated a review of clinical guideline updates and regulatory approvals that materially affect treatment pathways, ensuring alignment between clinical evidence and commercial implications.

Throughout, ethical standards for interview consent and data confidentiality were maintained, and limitations are transparently acknowledged where public data are incomplete or where evolving clinical evidence could alter strategic implications. The methodology emphasizes reproducibility and practical relevance, enabling stakeholders to adapt the analytical framework to their internal decision processes.

Concluding synthesis emphasizing the imperative for integrated clinical, supply-chain, and commercial approaches to translate therapeutic advances into sustained patient access

In conclusion, the tuberculosis therapeutics landscape is at an inflection point where clinical innovation, diagnostics integration, and supply-chain resilience collectively determine which therapies will achieve routine use. Shorter, all-oral regimens and targeted use of novel agents offer substantive benefits for patient adherence and programmatic delivery, but their impact depends on reliable diagnostics, secure supply chains, and pragmatic procurement approaches. Trade-policy developments and tariff measures introduce a new layer of operational risk that organizations must actively mitigate through supplier diversification and strategic localization.

Companies that pair clinical credibility with implementation capabilities-such as adherence support, diagnostic linkage, and flexible distribution models-will be best positioned to translate therapeutic advancements into sustained patient access. Public health programs and donors should continue to prioritize investments that strengthen the diagnostic-to-treatment continuum and support procurement mechanisms that preserve continuity of care. The path forward requires collaborative approaches that align commercial incentives with public health objectives to ensure that advances in therapy translate into better outcomes for patients living with tuberculosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of bedaquiline and delamanid access programs in high-burden MDR-TB countries accelerating treatment options
  • 5.2. Adoption of shorter pretomanid-based regimens for both drug-resistant and drug-sensitive tuberculosis improving compliance
  • 5.3. Development of novel oxazolidinone derivatives targeting persistent tuberculosis bacteria to reduce therapy length
  • 5.4. Integration of whole-genome sequencing into drug susceptibility testing to personalize multimodal tuberculosis treatment
  • 5.5. Surge in fixed-dose combination formulations tailored for pediatric tuberculosis to enhance dosing accuracy and adherence
  • 5.6. Regulatory approvals of second-generation nitroimidazole compounds aimed at overcoming drug resistance in TB strains

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Drugs Market, by Route Of Administration

  • 8.1. Injectable
  • 8.2. Oral

9. Tuberculosis Drugs Market, by Treatment Regimen

  • 9.1. Individualized Regimen
  • 9.2. Long Course
  • 9.3. Short Course

10. Tuberculosis Drugs Market, by Tuberculosis Type

  • 10.1. Extrapulmonary
  • 10.2. Pulmonary

11. Tuberculosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Tuberculosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Tuberculosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tuberculosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Johnson & Johnson
    • 15.3.2. Lupin Limited
    • 15.3.3. Cipla Limited
    • 15.3.4. Viatris Inc
    • 15.3.5. Sun Pharmaceutical Industries Limited
    • 15.3.6. Otsuka Pharmaceutical Co., Ltd.
    • 15.3.7. Dr. Reddy's Laboratories Limited
    • 15.3.8. Teva Pharmaceutical Industries Limited
    • 15.3.9. Glenmark Pharmaceuticals Limited
    • 15.3.10. F. Hoffmann-La Roche Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 79. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 81. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 90. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 100. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 104. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 119. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 130. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 140. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 141. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 162. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 163. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 172. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 173. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 192. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 193. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 202. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 203. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 212. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 213. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 223. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 231. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 239. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 247. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 263. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 271. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 279. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 286. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 287. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 294. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 295. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 302. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 303. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 310. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 311. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 318. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 319. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 326. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH KOREA TUBERCULOSI